Firstcall research report onCipla
Cipla is incorporated by Khwaja Abdul Hamied in 1935; he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakhs.
Cipla has over 34 state-of-the-art manufacturing units which have been approved by various Ministries of Health and Regulatory Authorities like USFDA, WHO, MCC-South Africa, MHRAUK, TGA-Australia among others. With over 2000 products in 65 therapeutic areas, Cipla’s product portfolio comprises of Active Pharmaceutical Ingredients (APIs), Formulations forHuman and Animal Healthcare and OTC products. Cipla has the technological prowess of manufacturing products in most dosage forms across therapeutic categories, which offers the company a unique competitive advantage. The Company’s R&D centre primarily focuses towards developing innovative products and drug delivery systems and has given the country and the world many ‘Firsts.’ This includes the revolutionary HIV/AIDS cocktail for less than a ‘Dollar a Day.’
Cipla is one of the largest exporters of pharmaceutical products from India and has a strong presence in over 170 countries. The company’s portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in FY 14 was 1.67 billion USD. As part of its international business, Cipla enters into strategic alliances and agency arrangements for product registration, development and distribution of its products. It also provides technological consultancy services for pharmaceutical projects in developed markets, particularly the U.S. and Europe. In addition, the company also maintains long-standing relationships with non-governmental organizations and institutions outside India. Cipla has earned a name for maintaining world-class quality across all its products and services. With the dedication of its 20,000 employees, Ciplacontinues to support, improve and save millions of lives with its high-quality drugs and innovative devices and is focused towards its commitment that ‘None shall be denied.
>>At the current market price of Rs.511.45, the stock P/E ratio is at 29.15 x FY15E and 26.34 x FY16E respectively.
>>Earning per share (EPS) of the company for the earnings for FY15E and FY16E is seen at Rs.17.54 and Rs.19.42 respectively.
>>Net Sales and PAT of the company are expected to grow at a CAGR of 13% and 1% over 2013 to 2016E respectively.
>>On the basis of EV/EBITDA, the stock trades at 18.11 x for FY15E and 16.14 x for FY16E.
>>Price to Book Value of the stock is expected to be at 3.57 x and 3.17 x respectively for FY15E and FY16E.
We recommend ‘BUY’ in this particular scrip with a target price of Rs.573.00 for Medium to Long term investment.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Read More
